Markus Müschen, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
muschen_markus

Professor, Department of Laboratory Medicine, UCSF
Program Co-Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

markus.muschen@ucsf.edu

Phone: (415) 502-0388 (voice)
Box 0134, UCSF
San Francisco, CA 94143-0134

View on UCSF Profiles


Additional Websites


Education

University of Nantes, Nantes, France, B.Sc., 1996, Immunology
Institut Pasteur, Paris, France, 1997, Immunology
Heinrich-Heine-Universität Düsseldorf, MD/PhD, 1999, Molecular Biology
University of Cologne, Germany, Intern/Resident, 1999, Hematology/Oncology
Institute for Genetics, University of Cologne, Postdoc, 2000, Genetics
University of Chicago, IL, Postdoc, 2001, Molecular Genetics
University of Cologne, Germany, Postdoc, 2002, Immunology


Professional Experience

  • 1994-1999
    Doctoral thesis in Biochemistry and Molecular Biology, summa cum laude (Mentor: Helmut Sies)
  • 1997-1999
    Internship and Residency in Hematology and Oncology (Mentor: Volker Diehl)
  • 1999-2000
    Postdoctoral fellow, Institute for Genetics, Cologne (Mentor: Klaus Rajewsky and Ralf Küppers)
  • 2000-2001
    Postdoctoral fellow, University of Chicago (Mentor: Janet D Rowley)
  • 2001-2002
    Postdoctoral fellow, Institute for Immunology, Cologne (Mentor: Martin Krönke)
  • 2002-2004
    Assistant Professor of Immunology Associate Professor of Stem Cell Biology (C3; with tenure), Heinrich-Heine-Universität Düsseldorf, Germany
  • 2006-2010
    Associate Professor of Pediatrics, Biochemistry and Molecular Biology, USC; Adjunct Faculty Appointment, Department of Biochemistry and Molecular Biology Program Leader, Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
  • 2006-2010
    Director, Leukemia Research Program, Childrens Hospital Los Angeles, Los Angeles, CA
  • 2010-present
    Professor, Departments of Laboratory Medicine and of Pathology, University of California San Francisco, San Francisco, CA

Honors & Awards

  • 1999
    Doctoral Thesis Award of the German Association for Hematology and Oncology (DGHO)
  • 2000
    Postdoctoral Fellowship Award of the Cancer Research Institute, New York, NY
  • 2001
    Emmy-Noether Young Investigator Award, The German Science Foundation (DFG)
  • 2001
    Stem Cell Research Investigator Award, The State of North-Rhine-Westphalia
  • 2002
    Best Habilitation Thesis of the Year, School of Medicine, University of Cologne, Germany
  • 2003
    Fritz Melchers Award for Immunology, the German Association for Immunology
  • 2006
    Leukemia Clinical Research Award, The German Association for Hematology and Oncology
  • 2006
    Honorary Professor of the Xinxiang Medical University, Xinxiang, P.R. China
  • 2009
    Section Editor for Acute Lymphoblastic Leukemia (ALL), Leukemia
  • 2009-present
    Study section member, Leukemia and Lymphoma Society, DOD Hematologic Malignancies Panel, NYStem (New York Stem Cell Research Agency)
  • 2010
    Editorial Board Biological Chemistry; Associate Editor Blood Cancer Journal
  • 2010-present
    Abstract Reviewer, American Society of Hematology
  • 2010
    Scholar Award, The Leukemia and Lymphoma Society

Selected Publications

  1. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014 Feb; 46(2):116-25.
    View on PubMed
  2. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A, Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013 Aug; 19(8):1014-22.
    View on PubMed
  3. Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 3; 121(1):148-55.
    View on PubMed
  4. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012 Nov 13; 22(5):656-67.
    View on PubMed
  5. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74.
    View on PubMed
  6. Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Oct 13; 118(15):4174-8.
    View on PubMed
  7. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011 Aug 25; 118(8):2191-9.
    View on PubMed
  8. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 May 19; 473(7347):384-8.
    View on PubMed
  9. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15; 17(10):3219-32.
    View on PubMed
  10. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal. 2011; 4(166):ra18.
    View on PubMed
  11. Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010 Oct 1; 70(19):7411-20.
    View on PubMed
  12. Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med. 2010 Jun 7; 207(6):1209-21.
    View on PubMed
  13. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 2010 Jun 1; 70(11):4346-56.
    View on PubMed
  14. Müschen M. Genetic relicts from the origin of ALL. Blood. 2010 Apr 29; 115(17):3424-5.
    View on PubMed
  15. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010 Feb 4; 115(5):1049-53.
    View on PubMed
  16. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009 Sep 8; 16(3):232-45.
    View on PubMed
  17. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009 Aug 3; 206(8):1739-53.
    View on PubMed
  18. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008 Dec 12; 135(6):1130-42.
    View on PubMed
  19. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med. 2007 May 14; 204(5):1157-66.
    View on PubMed
  20. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 2007 Mar; 26(3):323-33.
    View on PubMed

Go to UCSF Profiles, powered by CTSI